Пути оптимизации лечения детей с заболеваниями дыхательных путей и лор-органов

Abstract

Острые респираторные заболевания занимают одно из ведущих мест среди инфекционных болезней детского возраста. Сегодня большое количество исследований проводится в направлении усовершенствования методов лечения инфекционной патологии, в частности изучения эффективности и расширения возможностей применения в практической медицине бактериоцинов, основным источником которых являются грамположительные бактерии. Бактериоцины представляют собой антимикробные пептиды, обладающие широким противомикробным спектром действия. В частности, Streptococcus salivarius K12 является микроорганизмом, продуцирующим бактериоцины I класса (лантибиотики), способные интенсивно подавлять рост Streptococcus pyogenes, Streptococcus pneumonia, Haemophilus influenza и Moraxella catarrhalis, которые являются основными этиологическими факторами респираторных инфекций у детей. Цель. Изучение эффективности и безопасности применения препарата Бактоблис® (саше) на основе Streptococcus salivarius K12 и витамина D3 в комплексном лечении острых тонзиллитов, риносинуситов, стоматитов и отитов у детей...

Introduction. Acute respiratory diseases occupy one of the leading places among infectious diseases of childhood. Today, a large number of studies is carried out in the direction of studying the eff ectiveness and expanding the possibilities of using probiotics in practical medicine, particularly lantibiotics. In particular, Streptococcus salivarius K12 is a microorganism that produces the class I bacteriocins (lantibiotics) that can intensely inhibit the growth of Streptococcus pyogenes, Streptococcus pneumonia, Haemophilus infl uenza, and Moraxella catarrhalis that are signifi cant etiological factors of respiratory infections in children. Purpose. To study the effi cacy and safety of using the drug Bactoblis® (sachet) based on Streptococcus salivarius K12 and vitamin D in the complex treatment of acute upper respiratory tract diseases in children. Materials and methods. An open non-randomized clinical study was conducted with the participation of 55 patients aged from 3 to 7 years with acute respiratory infections of the upper respiratory tract (rhinosinusitis, tonsillitis, stomatitis, otitis media). The main group included 35 children, who received SsK12 in complex treatment for 10 days. The control group consisted of 20 children, who were prescribed the standard therapy without probiotic. The children of the main group, along with the main therapy, received Bactoblis® in the form of sachet based on Streptococcus salivarius K12. Evaluation of the eff ectiveness was carried out on the base of studying the dynamics of regression of clinical symptoms during a 10-day course of use. Results. The obtained results clearly show the eff ectiveness of complex treatment of children in the main group, which is characterized by a signifi cant improvement of the course of sinusitis, tonsillitis and stomatitis (p<0.01) and is manifested by a more rapid regression of clinical symptoms. The resulting eff ect in the form of decrease of duration of the disease by 2 days on average is implemented due to colonization of the oral mucosa and nasopharynx with the Streptococcus salivarius K12 strain and displacement of pathogenic microfl ora. Conclusion. Bactoblis® in the form of sachet is able to reliably reduce the duration of acute respiratory pathology, as well as the frequency of use of antibacterial drugs in this category of patients, which expands the possibility of using Streptococcus salivarius K12 in the complex treatment of diseases of the respiratory tract in children during exacerbation.